Clinical Trial Update: Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating interleukin-12 for treatment of severe nontuberculous mycobacterial infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nontuberculous Mycobacterial Infection
• Nontuberculous Mycobacterial Infections

Drugs mentioned

• Interleukin-12 (interleukin-12)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Atypical Mycobacterium Infection | Phase 1 | Status: COMPLETED